Amgen Partners with Ro to Improve Access to Obesity Treatments and GLP-1 Medications

Amgen and Ro Join Forces to Enhance Access to Obesity Treatments

Amgen collaborates with Ro, a direct-to-patient healthcare company, to research barriers to obesity treatment access, focusing on GLP-1 medications. This partnership aims to leverage Ro's vast de-identified data to uncover real-world challenges that patients and healthcare providers face in obtaining these critical therapies. Zach Reitano, CEO of Ro, emphasizes the urgency of improving access for millions of Americans who stand to benefit from obesity treatments, stating that real impact necessitates scale. This initiative specifically targets insurance coverage issues surrounding GLP-1s, as previous studies have primarily concentrated on policy-level data rather than individual patient experiences.

The collaboration intends to delve into the intricacies of prior authorizations, a key requirement for healthcare providers seeking coverage for GLP-1 medications. By analyzing trends in these authorizations, the research aims to identify gaps in insurance coverage and enhance understanding of the criteria that determine eligibility for treatments. This effort is crucial in empowering both patients and healthcare providers, ensuring that those who are clinically eligible can access the necessary therapies. The insights gained from this research could not only enhance patient experiences but also inform future therapy developments within the obesity treatment landscape.

Amgen's commitment to observational research is seen as instrumental in advancing patient care and addressing the complexities of obesity treatment access. The collaboration with Ro aims to dismantle existing barriers, facilitating broader access to next-generation obesity therapies as they become available. As the research progresses, Amgen anticipates translating the findings into actionable strategies that will enhance the overall landscape of obesity treatment, ultimately improving health outcomes for patients nationwide.

In addition to the collaboration with Ro, Amgen continues to innovate in obesity management with its promising drug, MariTide. Designed for monthly use, clinical trials indicate that MariTide can help patients sustain weight loss for up to two years. Amgen CEO Bob Bradway highlights the importance of patient engagement in treatment persistence and mentions exploring various dosing options, including potentially quarterly administration.

Moreover, Amgen's recent acquisition of Horizon Therapeutics aligns with its focus on biologics and autoimmune conditions. Bradway reports that the integration is proceeding smoothly, with the company eager to explore new therapeutic avenues for autoimmune disorders, further solidifying Amgen's commitment to leveraging its strengths in the biopharmaceutical sector.